Akèy › Karsinòm Selil Merkel
Etid klinik pou Karsinòm Selil Merkel ap rekrite nan Etazini
24 etid pou Karsinòm Selil Merkel ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX6 etid
- Boston, MA5 etid
- Tampa, FL4 etid
- New York City, NY4 etid
- San Antonio, TX4 etid
- Seattle, WA3 etid
- Queens, NY3 etid
- Jacksonville, FL3 etid
- Arlington, VA3 etid
- Pittsburgh, PA3 etid
- Miami, FL3 etid
- Los Angeles, CA3 etid
- St. Louis, MO3 etid
- Washington, DC3 etid
- Nashville, TN3 etid
Pa eta
- Florid11 etid
- Kalifòni5 etid
- Maryland3 etid
- Massachusetts5 etid
- Michigan5 etid
- Missouri3 etid
- New Jersey3 etid
- New York4 etid
- North Carolina3 etid
- Pennsylvania4 etid
- Tennessee3 etid
- Texas8 etid
- Virginia3 etid
- Washington4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07285044Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05583708Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Ap rekriteFaz 1
Laj 18 a 100 · Tout sèks · Mizajou Sep 22, 2026 · NCT07006727Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Ap rekriteFaz 1/2
Laj 18 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT06814496Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 100 Years · Tout sèks · Mizajou Sep 22, 2026 · NCT02471352A Study of CRD3874-SI in People With Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT06021626Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Sep 4, 2026 · NCT02479698Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT05896839Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 16 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05269381A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07115043A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT05859074A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07749586Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT05100095Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 25, 2026 · NCT04975152MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT05076760Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 17, 2026 · NCT06947928EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Ap rekriteFaz 2
Laj 18 a 99 · Tout sèks · Mizajou Mar 10, 2026 · NCT06223659Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 18, 2026 · NCT05496036TIL Therapy in cSCC and MCC
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT07288073IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 15, 2025 · NCT06940440A Beta-only IL-2 ImmunoTherapY Study
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2025 · NCT05086692Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.